Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report suggests that for prostate cancer patients with cardiovascular disease, prescribing the GnRH antagonist degarelix may reduce cardiac events compared to using GnRH agonists, although prescribing should consider potential cardiac risks, particularly in patients with pre-existing conditions or older age.

This study reported that CCT oligodeoxynucleotide induced patchy hair loss in male mice with specific genetic traits, suggesting gender and genetic preferences in immune response.

Men with early balding should be checked for metabolic syndrome, as there's a link between the two.

This chapter reviews various mucocutaneous manifestations of endocrine disorders and provides illustrative images of these clinical features, but reports no new research findings.

Iron supplements may reverse premature graying in iron-deficient individuals; ingrown nails are common in diabetics with certain risk factors; topical finasteride may reduce scalp DHT as effectively as oral finasteride; monilethrix treatment is challenging but some medications can help.

Iron supplements may reverse premature hair graying caused by iron deficiency.

The article concludes that hair loss has many causes and treatments, with medication options like finasteride and minoxidil for men, and minoxidil, hormones, or iron for women, while warning against unproven remedies.

This study found no significant correlation between serum testosterone or DHEAS levels and the severity of acne or FPHL in a localized female population, but noted most patients had low testosterone levels.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

The guidelines advise against using testosterone and DHEA in women for most conditions due to safety and effectiveness concerns, but suggest considering testosterone for postmenopausal women with low sexual desire.

This study concluded that current cross-sex hormone treatments for trans men and trans women are effective with a low risk of side effects in the short term, though they did observe specific clinical changes.

This research observed that oral testosterone replacement therapy significantly increases cardiovascular risk, while effects of injected or transdermal therapy on cardiovascular risk were not significant, prompting further investigation into these methods.

Dihydrotestosterone gel improved well-being and sexual function in older men without negatively affecting prostate health.

This review discusses the free hormone hypothesis for measuring "free" testosterone and critiques its theoretical basis and clinical application, noting it lacks critical empirical testing and has inconsistent utility in assessing androgen status.

This review highlights the efficacy of transdermal testosterone therapy in improving sexual function in women with hypoactive sexual desire disorder, though approved formulations and long-term safety data are limited.

This systematic review suggests that current evidence does not support routinely discontinuing gender-affirming hormone treatments before surgery, especially testosterone and spironolactone, due to limited data on related perioperative risks.

This study found that testosterone-enanthate increased red blood cell production and altered iron homeostasis in older hypogonadal men without being affected by finasteride, indicating these effects do not require type II 5α-reductase enzyme activity.

This article reviews the use of cross-sex hormonal therapy in transmen and reports that it is reasonably safe, suggesting monitoring should be frequent initially but can be less frequent over time.

This review examines various androgen deprivation therapy methods for advanced prostate cancer, highlighting benefits and potential cardiovascular and sexual adverse effects, but reports no new clinical results.

This mini-review discusses the role of androgens, specifically testosterone and dihydrotestosterone, in the pathogenesis of autoimmune liver diseases and reports no new results.

This review discusses the potential of DHEAS and testosterone treatments to increase muscle mass in older men with sarcopenia, while effects on muscle function and physical performance remain unclear, and calls for further research on optimized approaches.

This study suggests that gender-affirming testosterone therapy in transgender men is generally safe and effective with adequate screening and monitoring, although high-quality long-term studies are lacking.

This review describes current medical and surgical treatments for transgender men, highlighting the effectiveness and general tolerability of hormone treatment, and suggesting that surgical benefits often surpass associated risks, although it reports no new clinical findings.

This review highlights the mixed roles of testosterone in COVID-19, noting both potential benefits through anti-inflammatory effects and risks due to increased virus entry, with low testosterone linked to increased severity.

This review examines the benefits and potential risks of androgen replacement therapy for male hypogonadism but reports no new clinical results; the authors highlight the need for careful risk assessment, especially in older men.

This guideline provides evidence-based recommendations for prescribing testosterone therapy to women with hypoactive sexual desire disorder, noting a moderate therapeutic benefit but highlighting limited data and regulatory challenges.

This article reviews emerging opportunities and challenges in male reproductive medicine, including advancements and unmet needs in erectile dysfunction, androgen deficiency, and fertility, but reports no new clinical findings.

In this study, the authors observed that testosterone therapy shortened the QTc interval and normalized T-wave morphology in men with acquired LQTS or TdP linked to hypogonadism, suggesting testosterone may be helpful in treatment.

In this review, the authors examined guidelines and literature on the non-operative treatment of gender dysphoria, highlighting the importance of personalized, multidisciplinary care, and noting that such treatment is generally safe and effective according to WPATH and Endocrine Society recommendations.

This review discusses the evaluation of hyperandrogenemia in women and hypogonadism in men across different life stages and presents biomarkers used for diagnosing male hypogonadism, reporting no new clinical results.